Polymyxin B Pharmacodynamics in the Hollow-Fiber Infection Model: What You See May Not Be What You Get.

Antimicrobial Agents and Chemotherapy
Michael MaynardArnold Louie

Abstract

Dose range studies for polymyxin B (PMB) regimens of 0.75 to 12 mg/kg given every 12 h (q12h) were evaluated for bacterial killing and resistance prevention against an AmpC-overexpressing Pseudomonas aeruginosa and a blaKPC-3-harboring Klebsiella pneumoniae in 10-day in vitro hollow-fiber models. An exposure-response was observed. But all regimens failed due to regrowth. Lower-dose regimens amplified isolates that expressed transient, lower-level adaptive resistance to PMB (MICs ≤ 4 mg/liter). Higher PMB dosages amplified isolates that expressed this resistance mechanism, a higher-MIC "moderately stable" adaptive resistance, and a higher-MIC stable resistance to PMB. Failure of the highest dose regimens was solely due to subpopulations that expressed the two higher-level resistances. Total and bioactive PMB concentrations in broth declined below targeted PK profiles within hours of treatment initiation and prior to bacterial regrowth. With treatment failure, the total PMB measured in bacteria was substantially higher than in broth. But the bioactive PMB in broth and bacteria were low to nondetectable. Together, these findings suggest a sequence of events for treatment failure of the clinical regimen. First, PMB concentrations i...Continue Reading

References

Oct 2, 1979·Biochemistry·M Schindler, M J Osborn
Dec 11, 2003·Microbiology and Molecular Biology Reviews : MMBR·Hiroshi Nikaido
Aug 30, 2005·Antimicrobial Agents and Chemotherapy·Vincent H TamRussell E Lewis
Nov 1, 1947·Journal of Bacteriology·P G Stansly, M E Schlosser
Jan 19, 2007·The Journal of Physical Chemistry. B·Adrià ClausellYolanda Cajal
Sep 17, 2010·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Matthew E FalagasDimitrios K Matthaiou
Aug 21, 2013·Antimicrobial Agents and Chemotherapy·Yanina DubrovskayaSapna A Mehta
Feb 18, 2014·Journal of Pharmaceutical and Biomedical Analysis·Soon-Ee CheahRoger L Nation
Oct 31, 2014·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·M MonacoG M Rossolini
Jul 1, 2015·Antimicrobial Agents and Chemotherapy·F Docobo-PérezW W Hope
Aug 10, 2016·Cold Spring Harbor Perspectives in Medicine·Michael J TrimbleRobert E W Hancock
Sep 21, 2016·Emerging Infectious Diseases·Flávia BartolletiJorge Luiz Mello Sampaio
Oct 30, 2016·International Journal of Antimicrobial Agents·Thien B TranJian Li
Sep 30, 2017·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Jenna CovelliGauri G Rao
Nov 28, 2017·Annals of Clinical Microbiology and Antimicrobials·David M JacobsGauri G Rao
Nov 16, 2018·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Patrik Mlynarcik, Milan Kolar
Jan 23, 2019·Journal of Clinical Pharmacy and Therapeutics·Karen P H MattosPatricia Moriel

❮ Previous
Next ❯

Software Mentioned

Analyst
HFIM

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Physics in Medicine and Biology
Simon Cherry
The American Journal of Physiology
T GrémeauxY Le Marchand-Brustel
The Journal of Immunology : Official Journal of the American Association of Immunologists
Davide FerrariFrancesco Di Virgilio
© 2021 Meta ULC. All rights reserved